SPT for Sensitization of Collagen Dressing

Last updated: August 23, 2024
Sponsor: Covalon Technologies Inc.
Overall Status: Completed

Phase

N/A

Condition

Allergy (Pediatric)

Allergy

Allergies & Asthma

Treatment

ColActivePlus Collagen Matrix Dressing

Clinical Study ID

NCT06271993
23-233
  • Ages 18-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The goal of this clinical trial is to determine the sensitization (contact allergy) potential of the test product ColActive Plus Collagen Matrix Dressing after a skin prick test on the skin of healthy human subjects. The main question it aims to answer is:

• Does the product induce any sensitization (contact allergy) after a skin prick using a UniTest PC (pain control) device in healthy human subjects? Participants will have the test product and both positive and negative controls applied, and skin response will be evaluated by an allergist at 15 minutes, 6 hours, and 24-48 hours post-application to see if sensitization occurs.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age: 18-70

  • Sex: Male & Female

  • Fitzpatrick: I-V, minimum 10% of panel Fitzpatrick V.

  • Individuals who will be able to read, understand and give an informed consentrelating to the study they are participating in.

  • Individuals who will be free of any dermatological or systemic disorder, which inthe Investigator's opinion, could interfere with the study results.

  • Individuals who will be in general good health and who will complete a preliminarymedical history form mandated by the testing facility.

  • Individuals who will be able to and agree to cooperate with the Investigator andclinical staff.

  • Individuals who will agree to have test products applied in accordance with theprotocol and are able to complete the full course of the study.

  • Individuals who have not participated in a similar study in the past 30 days.

  • Individuals who agree to refrain from sun tanning/bathing and prolonged exposure tosunlight (outdoors).

  • Individuals who are willing to refrain from wetting, wiping, cleanse, and coveringthe test sites (volar surface of the forearms) between the baseline and up to 48-hour time points.

  • Female volunteers who are willing to undergo a urine pregnancy test.

  • Individuals willing to refrain from vitamin C (Emergen-C), orange juice and vitaminwater for the study duration and two days prior to the SPT test.

Exclusion

Exclusion Criteria:

  • Individuals who are currently taking any medications (topical or systemic) that maymask or interfere with the test results (specifically, corticosteroids, topicaland/or systemic [except nasal steroids], non steroidal anti-inflammatory drugs [e.g.ibuprofen, Advil, Motrin, aspirin > 325mg/day], antihistamines, and topical/oralimmunosuppressive medications).

  • Individuals who have a history of any acute or chronic disease that might interferewith or increase the risk on study participation. (e.g., systemic lupuserythematosus, rheumatoid arthritis, HIV positive).

  • Individuals who are diagnosed with chronic skin allergies (atopic dermatitis/eczema)or recently treated skin cancer within the last 12 months.

  • Individuals who have damaged skin in close proximity to test sites (e.g., sunburn,uneven skin pigmentation, tattoos, scars, excessive hair, active acne papules orother disfigurations).

  • Individuals who control their diabetes using insulin.

  • Individuals with any history, which in the Investigator's opinion, indicates thepotential for harm to the subject or places the validity of the study in jeopardy.

  • Female volunteers who indicate that they are pregnant or are planning to becomepregnant or nursing.

  • Individuals with a known history of hypersensitivity to any cosmetics, personal careproducts, fragrances, and/or adhesives.

  • Individuals that have a history of dermatographism.

  • Individuals have a history of frequent skin irritation.

  • Employees of ALS.

  • Individuals with a known fish allergy.

Study Design

Total Participants: 27
Treatment Group(s): 1
Primary Treatment: ColActivePlus Collagen Matrix Dressing
Phase:
Study Start date:
February 08, 2024
Estimated Completion Date:
February 16, 2024

Study Description

This will be a single center, with no randomization or blinding, study design in 30 healthy adult subjects, age 18-70 years. Based on prior experience approximately 30 subjects will be enrolled to ensure 20 subjects complete the study.

Skin response to the test product and both positive and negative controls will be evaluated and measured by an allergist. If the measured diameter is ≥3mm in response to the test product with expected reactions to both the positive and negative controls, the site will be considered a positive allergen.

Connect with a study center

  • ALS Beauty and Personal Care

    Torrance, California 90501
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.